FDA Approves Subcutaneous Nivolumab Across Existing Solid Tumor Indications
On December 27, 2024, subcutaneous nivolumab (Opdivo Qvantig) was approved by the FDA in all previously approved adult solid tumor indications of the agent as monotherapy or monotherapy maintenance or in combination with chemotherapy or cabozantinib (Cabometyx). 1
Squibb announced that the U.S. FDA granted approval for Opdivo Qvantig injection for subcutaneous use, a combination product ...
The US Food and Drug Administration (FDA) on Friday approved nivolumab and hyaluronidase-nvhy, under the trade name Opdivo ...
For patients with microsatellite-instability-high (MSI-H) or mismatch-repair-deficient (dMMR) metastatic colorectal cancer ...
In January 2024, the FDA approved erdafitinib (Balversa) for adult patients with locally advanced or metastatic urothelial ...
Kara Kelly, MD, chair of pediatrics, Roswell Park Oishei Children's Cancer and Blood Disorders Program, shares findings on ...
Results from the phase 3 TiNivo-2 trial suggest that immune checkpoint inhibitor rechallenge should generally be discouraged ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback